FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Danske Bank A/S(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose r ...

The air suspension systems market is highly fragmented and the key manufacturers are deploying several organic and inorganic growth strategies to compete with the existing players in the market. The biggies are heavily investing in research and development activities to leverage advancements to the features of suspension systems. They are making attempts for easing the job of autonomous vehicle manufacturers to make automobiles with high speed, backed by high safety.NEWARK, Del, Jan. 21, 2025 (GLOBE NEWSWIR ...

Immense demand for nutritious seeds, fruits, and algae shapes a vibrant superfood landscape. Sustainable farming practices, modern packaging, and research-backed benefits place superfoods at the heart of future diets.New Delhi, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The global superfoods market was valued at US$ 194.4 billion in 2024 and is expected to reach US$ 405.1 billion by 2033, growing at a CAGR of 8.5% during the forecast period 2025–2033. In the evolving world of nutrition, superfoods have emerged as th ...

Clinical Trial Results - The Phase 3 MARIPOSA study demonstrated that amivantamab plus lazertinib significantly improved progression-free survival (PFS) compared to osimertinib, with a median PFS of 23.7 months versus 16.6 months, reducing the risk of disease progression or death by 30% [7] - Median overall survival (OS) for amivantamab plus lazertinib is expected to exceed one year compared to osimertinib, marking a clinically meaningful improvement [1][3] - The combination therapy showed a nine-month improvement in median duration of response (DOR) compared to osimertinib (25.8 months vs. 16.8 months) [7] Regulatory Approval - The European Commission (EC) approved the combination of amivantamab and lazertinib for first-line treatment of adult patients with advanced NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations [1][5] - This approval follows a Type II variation extension for amivantamab in December 2024, allowing its use in combination with lazertinib for the same indication [5] Safety Profile - The safety profile of amivantamab plus lazertinib was consistent with earlier studies, with mostly Grade 1 or 2 adverse events (AEs) [4] - Common treatment-emergent adverse events (TEAEs) included paronychia (68%), infusion-related reactions (63%), and rash (62%) [4] - The rate of discontinuation due to treatment-related AEs was 10%, and the rate of interstitial lung disease was 3% [4] Market and Industry Impact - NSCLC accounts for 85% of lung cancer cases in Europe, with EGFR mutations present in 10-15% of Western patients and 40-50% of Asian patients [14][15] - The five-year survival rate for advanced NSCLC patients with EGFR mutations treated with EGFR TKIs is less than 20%, highlighting the unmet need for improved therapies [15] - The approval of amivantamab plus lazertinib represents a significant advancement in NSCLC treatment, offering a chemotherapy-free regimen with potential to extend life expectancy [4][5] Study Design and Methodology - The MARIPOSA study enrolled 1,074 patients and evaluated amivantamab plus lazertinib versus osimertinib and lazertinib alone in first-line treatment of EGFR-mutated NSCLC [6] - The study included serial brain MRI imaging, as nearly 30% of patients develop brain metastases, and CNS events were part of the primary PFS endpoint [8] - Secondary endpoints included overall survival (OS), overall response rate (ORR), duration of response (DOR), and intracranial PFS [6]

Renewable Energy Cost Trends - Solar energy has become the cheapest form of energy for new plant construction, with prices dropping by 90% over the past decade [2] - Wind energy costs have fallen by approximately 60%, further bolstering the economic viability of renewable sources [2] Green Hydrogen Development - Green hydrogen, produced from renewable sources, is critical for achieving true decarbonization, differentiating it from "gray" or "blue" hydrogen produced from fossil fuels [3] - Japan's National Hydrogen Strategy outlines a scenario where the country could fully decarbonize by the 2040s using renewable energy and hydrogen, achieving higher energy security at a lower cost than the current system [3] - NewHydrogen is developing ThermoLoop, a breakthrough technology that uses water and heat rather than electricity to produce the world's lowest cost green hydrogen [8][9] - Inexpensive heat for green hydrogen production can be obtained from concentrated solar, geothermal, nuclear reactors, and industrial waste heat [10] Energy Infrastructure and Storage - Significant shift in energy infrastructure planning is necessary to incorporate energy storage solutions [2] - Electric vehicles (EVs) can serve as mobile energy storage, with vehicle-to-grid (V2G) technology enhancing grid flexibility and resilience [4] - Mandated V2G capability in all new EVs could allow them to return energy to the grid during periods of peak demand [4] Equitable Transition and Job Creation - Benefits of green hydrogen development, including job creation and environmental cleanup, should be equitably shared among all communities, especially those historically burdened by pollution [5] - Concentrated industrial hubs are proposed as ideal test cases for demonstrating the feasibility and benefits of green hydrogen, providing a just and equitable transition [5] Market Potential - The green hydrogen economy is estimated by Goldman Sachs to have a future market value of $12 trillion [10]

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeDe La Rue plc(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint Br ...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeAlliance Pharma plc(c) Name of the party to the offer with which exempt principal trader is connected:Investec is fi ...

VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Hi-View Resources Inc. (‘Hi-View' or the ‘Company’) (CSE: HVW; OTCQB: HVWRF; FSE: B63) announces that planning has commenced for a follow-up exploration program at its 9,140 Hectare (“Ha”) Golden Stranger Project and Lawyers South, East and West claims located in British Columbia's prolific Toodoggone-Kemess porphyry Cu-Au region of north-central British Columbia (“Toodoggone”). The properties are contiguous to the Thesis Gold Inc. Lawyers-Ranch ...

Aktia Bank PlcStock Exchange Release 21 January 2025 at 10.00 a.m. Changes in the number of own shares held by Aktia Bank Plc Aktia Bank Plc has today, based on a decision made by the company's Board of Directors, divested a total of 15,856 own shares held by the company to 49 persons as a deferred payment based on the company’s remuneration programs.The divestment of own shares is based on the authorisation by the Annual General Meeting of Shareholders held on 3 April 2024. After the above-mentioned divest ...

Municipality Finance PlcStock exchange release 21 January 2025 at 10:00 am (EET) Municipality Finance issues USD 300 million benchmark under its MTN programme Municipality Finance Plc issues USD 300 million benchmark on 22 January 2025. The maturity date of the benchmark is 2 February 2029. The benchmark bear interest at a floating rate equal to Compounded SOFR plus 100 bps per annum. The benchmark is issued under MuniFin’s EUR 50 billion programme for the issuance of debt instruments. The offering circul ...